Back to Search
Start Over
Clinical Updates: KIDNEY CANCER. Updated data show OS benefit with adjuvant pembrolizumab in ccRCC.
- Source :
-
Urology Times . May2024, Vol. 52 Issue 5, p22-23. 2p. - Publication Year :
- 2024
-
Abstract
- The article discusses updated data as of 2024 which shows that adjuvant pembrolizumab (Keytruda) extended overall survival (OS) in patients with clear cell renal cell carcinoma (ccRCC) at medium or high risk of recurrence. It states that the therapy improved disease-free survival (DFS) and lowered distant and local disease recurrence. Also noted are the occurrences of immune-mediated adverse events (AE) and infusion reactions among patients.
- Subjects :
- *THERAPEUTIC use of monoclonal antibodies
*RISK assessment
*PLACEBOS
*DEATH
*CANCER relapse
*DRUG side effects
*PATIENT safety
*CLINICAL trials
*TERMINATION of treatment
*NEPHRECTOMY
*RENAL cell carcinoma
*DISEASE relapse
*PROGRESSION-free survival
*TUMOR classification
*OVERALL survival
*PATIENT aftercare
*EVALUATION
*DISEASE risk factors
Subjects
Details
- Language :
- English
- ISSN :
- 00939722
- Volume :
- 52
- Issue :
- 5
- Database :
- Academic Search Index
- Journal :
- Urology Times
- Publication Type :
- Periodical
- Accession number :
- 177110901